Skip to main content
Premium Trial:

Request an Annual Quote

GeneGo to Develop Data-Management Software for Cystic Fibrosis Foundation

NEW YORK (GenomeWeb News) — GeneGo today said it will work with the Cystic Fibrosis Foundation to develop a software suite to handle data from cystic fibrosis drug-development studies.  
The new platform, called MetaMiner, will include off-the-shelf GeneGo products such as MetaCore, MetaDrug, MetaLink, and MapEditor. MetaMiner will include -omics and small experiments specific to cystic fibrosis that have been annotated by GeneGo.
MetaMiner, which GeneGo plans to use in other collaborations, will be used by researchers conducting high-throughput screens and bioassays, and in this case will be customized for cystic fibrosis experiments.
"We hope this collaboration will better help us to understand the disease and potential therapies at the molecular level," Robert Beall, president and CEO of the Foundation, said in a statement.
Julie Bryant, GeneGo’s vice president of business development, said the collaboration “is the first in a series” of such alliances in which MetaMiner will be used to store and analyze data for disease research.
The platform will be available to the CFF in February, and to other collaborators through access licenses, GeneGo said. A CFF committee will oversee the research.
Financial terms of the agreement were not released.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.